Circulative biomarkers as predictors of cardiovascular events in patients after treatment of Hodgkin lymphoma
Aim. Nature development of lymphoma associates with increased risk of cardiovascular diseases. We aimed to evaluate the prognostic value of circulating NT-proBNP, galectin-3, and VE-cadherin in survivors of Hodgkin lymphoma. Methods: Surveys were given to Hodgkin lymphoma survivors who reached at...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Zaporizhzhia State Medical and Pharmaceutical University
2017-12-01
|
| Series: | Aktualʹnì Pitannâ Farmacevtičnoï ì Medičnoï Nauki ta Praktiki |
| Subjects: | |
| Online Access: | http://pharmed.zsmu.edu.ua/article/view/113558/110369 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849251401620783104 |
|---|---|
| author | B. B. Samura |
| author_facet | B. B. Samura |
| author_sort | B. B. Samura |
| collection | DOAJ |
| description | Aim. Nature development of lymphoma associates with increased risk of cardiovascular diseases. We aimed to evaluate the prognostic value of circulating NT-proBNP, galectin-3, and VE-cadherin in survivors of Hodgkin lymphoma.
Methods: Surveys were given to Hodgkin lymphoma survivors who reached at list partial response after treatment. Observation period was up to 3 years. ELISA method for measurements of circulating level of biomarkers was used.
Results: During observation period progression of Hodgkin lymphoma was proved in 8 patients, 4 persons were excluded for poor follow-up. Thirty four cumulative clinical events occurred in 11 patients (55%) within the follow-up, with their distribution being as follows: 2 cardiovascular deaths, 16 cardiac arrhythmias, 6 cardiac ischemic events, 1 stroke, 4 chronic heart failures and 5 hospital admissions for cardiovascular reasons. 4 deaths were not related with cardiovascular pathology or cardiovascular reasons.
Circulating level of NT-proBNP in patients without cardiovascular events and with cardiovascular events were 5.81 pg/ml (95% confidence interval [CI] = 3.21-8.41 pg/ml) and 12.74 pg/ml (95 % CI = 6.47-18.94 pg/ml) (р=0.072). In patients without cardiovascular events circulating level of galectin-3 was 5.91 pg/ml (95% confidence interval [CI] = 4.18-7.03 pg/ml) and in patients with cardiovascular events circulating level of galectin-3 was 14.33 pg/ml (95% CI = 5.99-16.18 pg/ml) (р=0.01). Circulating level of VE-cadherin in patients without cardiovascular events and with cardiovascular events were 0.40 pg/ml (95% confidence interval [CI] = 0.31-0.54 pg/ml) and 0.99 pg/ml (95% CI = 0.70-1.15 pg/ml) (р=0.02)
In multivariate logistic regression circulating NT-proBNP independently predicted cumulative cardiovascular events (odds ratio [OR] = 1,179; 95% CI = 1,043–1,334; р = 0.008) within 3 years of observation period.
Conclusion: Among patients after treatment of Hodgkin lymphoma increased circulating NT-proBNP may associate with increased cumulative cardiovascular events during 3 years. |
| format | Article |
| id | doaj-art-a769d5431cb84d4793c9e71a00f084d4 |
| institution | Kabale University |
| issn | 2306-8094 2409-2932 |
| language | English |
| publishDate | 2017-12-01 |
| publisher | Zaporizhzhia State Medical and Pharmaceutical University |
| record_format | Article |
| series | Aktualʹnì Pitannâ Farmacevtičnoï ì Medičnoï Nauki ta Praktiki |
| spelling | doaj-art-a769d5431cb84d4793c9e71a00f084d42025-08-20T03:56:58ZengZaporizhzhia State Medical and Pharmaceutical UniversityAktualʹnì Pitannâ Farmacevtičnoï ì Medičnoï Nauki ta Praktiki2306-80942409-29322017-12-01329630110.14739/2409-2932.2017.3.113558Circulative biomarkers as predictors of cardiovascular events in patients after treatment of Hodgkin lymphomaB. B. SamuraAim. Nature development of lymphoma associates with increased risk of cardiovascular diseases. We aimed to evaluate the prognostic value of circulating NT-proBNP, galectin-3, and VE-cadherin in survivors of Hodgkin lymphoma. Methods: Surveys were given to Hodgkin lymphoma survivors who reached at list partial response after treatment. Observation period was up to 3 years. ELISA method for measurements of circulating level of biomarkers was used. Results: During observation period progression of Hodgkin lymphoma was proved in 8 patients, 4 persons were excluded for poor follow-up. Thirty four cumulative clinical events occurred in 11 patients (55%) within the follow-up, with their distribution being as follows: 2 cardiovascular deaths, 16 cardiac arrhythmias, 6 cardiac ischemic events, 1 stroke, 4 chronic heart failures and 5 hospital admissions for cardiovascular reasons. 4 deaths were not related with cardiovascular pathology or cardiovascular reasons. Circulating level of NT-proBNP in patients without cardiovascular events and with cardiovascular events were 5.81 pg/ml (95% confidence interval [CI] = 3.21-8.41 pg/ml) and 12.74 pg/ml (95 % CI = 6.47-18.94 pg/ml) (р=0.072). In patients without cardiovascular events circulating level of galectin-3 was 5.91 pg/ml (95% confidence interval [CI] = 4.18-7.03 pg/ml) and in patients with cardiovascular events circulating level of galectin-3 was 14.33 pg/ml (95% CI = 5.99-16.18 pg/ml) (р=0.01). Circulating level of VE-cadherin in patients without cardiovascular events and with cardiovascular events were 0.40 pg/ml (95% confidence interval [CI] = 0.31-0.54 pg/ml) and 0.99 pg/ml (95% CI = 0.70-1.15 pg/ml) (р=0.02) In multivariate logistic regression circulating NT-proBNP independently predicted cumulative cardiovascular events (odds ratio [OR] = 1,179; 95% CI = 1,043–1,334; р = 0.008) within 3 years of observation period. Conclusion: Among patients after treatment of Hodgkin lymphoma increased circulating NT-proBNP may associate with increased cumulative cardiovascular events during 3 years.http://pharmed.zsmu.edu.ua/article/view/113558/110369NT-proBNPVE-cadheringalectin-3Hodgkin lymphomaprognosis |
| spellingShingle | B. B. Samura Circulative biomarkers as predictors of cardiovascular events in patients after treatment of Hodgkin lymphoma Aktualʹnì Pitannâ Farmacevtičnoï ì Medičnoï Nauki ta Praktiki NT-proBNP VE-cadherin galectin-3 Hodgkin lymphoma prognosis |
| title | Circulative biomarkers as predictors of cardiovascular events in patients after treatment of Hodgkin lymphoma |
| title_full | Circulative biomarkers as predictors of cardiovascular events in patients after treatment of Hodgkin lymphoma |
| title_fullStr | Circulative biomarkers as predictors of cardiovascular events in patients after treatment of Hodgkin lymphoma |
| title_full_unstemmed | Circulative biomarkers as predictors of cardiovascular events in patients after treatment of Hodgkin lymphoma |
| title_short | Circulative biomarkers as predictors of cardiovascular events in patients after treatment of Hodgkin lymphoma |
| title_sort | circulative biomarkers as predictors of cardiovascular events in patients after treatment of hodgkin lymphoma |
| topic | NT-proBNP VE-cadherin galectin-3 Hodgkin lymphoma prognosis |
| url | http://pharmed.zsmu.edu.ua/article/view/113558/110369 |
| work_keys_str_mv | AT bbsamura circulativebiomarkersaspredictorsofcardiovasculareventsinpatientsaftertreatmentofhodgkinlymphoma |